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Background: Information and pathobiological understanding about central demyelinat-
ing manifestation in patients, who primarily suffer from chronic inflammatory demyelinat-
ing polyneuropathy (CIDP), are scarce.
Methods: IFN-γ-response as well as antibodies against the (para)nodal antigens neuro-
fascin (NF)155 and NF 186 had been tested by Elispot assay and ELISA before clinical 
manifestation and at follow-up.
Case description and results: The patient described here developed a subacute brain-
stem syndrome more than 10 years after diagnosis of CIDP under low-dose maintenance 
treatment of intravenous immunoglobulins (IVIG). MRI revealed enhancing right-sided 
pontocerebellar lesion. CSF examination showed mild pleocytosis and elevated protein, 
and negative oligoclonal bands. Further diagnostics exclude differential diagnoses such 
as tuberculoma, sarcoidosis, or metastasis. Specific IFN-γ response against NF155 and 
NF186 as measured by Elispot assay was elevated before clinical manifestation. NF155 
and NF186 antibodies were negative. Escalation of IVIG treatment at 2 g/kg BW followed 
by 1.4 g/kg BW led to clinical remission albeit to a new asymptomatic central lesion. 
Follow-up NF155 and NF186-Elispot turned negative.
Conclusion: The case reported here with a delayed central manifestation after an ini-
tially typical CIDP and NF155 and NF186 T cell responses does not resemble described 
cases of combined central and peripheral demyelination but may reflect a novel subtype 
within the great clinical heterogeneity of CIDP.
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INtRoDUCtIoN
Multiple sclerosis (MS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are 
both demyelinating disorders of the nervous system with unknown underlying pathomechanisms. 
Whereas MS is restricted to the central nervous system, CIDP comprises demyelination of the 
peripheral nervous system. There are few reports in the literature about patients suffering from both, 
taBle 1 | Nerve conduction studies before brainstem symptoms.
Nerve DMl MCV CMap F-wave
Median Right 9 ms 34 m/s 3 mV 47 ms
Left 10.8 ms 31 m/s 2 mV 51 ms
Ulnar Right 8.2 ms 37 m/s 3.7 mV 51.4 ms
Left 8.3 ms 35 m/s 3.2 mV 58 ms
Peroneal Right n.d. n.d. n.d. n.d.
Tibial Right n.d n.d n.d n.d
DML, distal motor latency; MCV, motor nerve conduction; CMAP, compact motor 
action potential.
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CNS and PNS manifestation in similar extent (1, 2). However, 
only little is known about central manifestations other than 
cranial nerve involvement over the course of disease in patients, 
who primarily suffer from CIDP. Due to its heterogeneous mani-
festation, different autoimmune targets are likely to be relevant 




96-well plates (Millipore, Billerica, MA, USA) were coated 
with an IFN-γ-specific antibody (eBioscience, San Diego, CA, 
USA) at 4  µg/ml in sterile PBS overnight. After blocking with 
sterile PBS + 1% BSA (Sigma-Aldrich, St. Louis, MO, USA) for 
60–120 min, fresh PBMCs were added in a number of 4 × 105 cells/
well in presence of anti-CD28 antibody (eBioscience) at 2 µg/ml. 
Peripheral myelin antigens neurofascin (NF)155 and NF186 [as 
described (5); kindly provided by E. Meinl, Munich] were added 
at 40 µg/ml. To detect spontaneous IFN-γ secretion CTL-Test-
Medium (CTL, Cleveland, OH, USA) was used. CEF was used as 
positive control at a concentration of 10 µg/ml. It is a peptide pool 
containing 23 MCH class 1 restricted viral antigens (6). Plates 
were incubated at 37°C and 5% CO2 for 24 h. Mouse-antihuman 
IFN-γ biotin antibody (eBioscience) at concentration of 2 µg/ml 
conjugated to streptavidin-horseradish-peroxidase (BioLegend, 
San Diego, CA, USA) at 1:1,000 were used for detection. 
Plates were developed with 3-amino-9-ethyl carbazole reagent 
(Sigma-Aldrich, St Louis, MO, USA). The resulting spots were 
detected, counted, and analyzed via Elispot Reader (Autoimmun 
Diagnostika GmbH, Strassberg, Germany) and appendant iSpot 
04 Software. Spot forming unit (SFU) for each antigen triplicate 
was averaged and subtracted by average SFU of spontaneous 
IFN-γ secretion and then calculated for a cell amount of 106 cells.
patient Consent
The patient here gave her written consent as part of a cohort study 
before the study. She additionally gave her written informed con-
sent for the publication of this case report. The cohort study was 
approved by ethical committee of Charité University Medicine 
Berlin. All patients were recruited in the outpatient clinic of 
Charité Department of Neurology. For Elispot assay control, we 
included 16 age-matched patients suffering from non-immune 
neuropathies.
Description of the Case
The 56-year-old patient was diagnosed with CIDP in 1999 with 
a typical manifestation consisting of distal and proximal weak-
ness and sensory dysfunction of all extremities. The clinical 
evaluation revealed generally absent deep tendon reflexes, distal 
and proximal weakness, large fiber sensory involvement, and 
a tremor of the right arm. Nerve conduction studies revealed 
primary demyelinating neuropathy (Table 1). She had suffered 
from tuberculosis infection 1965, 1974, and 1978. In 2002, she 
was diagnosed with breast cancer treated by tamoxifen.
The patient received intravenous immunoglobulins (IVIG) 
treatment since 2004 with a dosage of 50  g at 4–10  weeks of 
treatment intervals (0.77  g/kg body weight) and was clinically 
stable for more than 10 years. In 2014, she subacutely developed 
progressive vertigo and a tendency to fall to the right side combined 
with nausea. In addition, she suffered from increasing problems 
with walking and climbing stairs. Clinical examination revealed a 
clear deterioration of the paresis but no nystagmus or other signs 
for vestibular involvement. Ear–nose–throat examination was 
without pathological finding. MRI demonstrated a right-sided 
pontocerebellar lesion adjacent to the upper cerebellar peduncle 
with incomplete peripheral enhancement. There was no concur-
rent pathological meningeal enhancement (Figure 1A).
As differential diagnosis tuberculoma, metastasis, sarcoidosis, 
MS, as well as central manifestation of CIDP were discussed and 
further diagnostic tests were performed. For that, CSF showed 
mild pleocytosis (seven cells) and elevated protein (136 mg/dl) 
with normal lactate levels, negative oligoclonal bands (OCB) 
without evidence for infection. Borrelia screening was negative. 
CT scan of the thorax showed two old, unchanged calcified gran-
ulomas in the left upper field of lung compatible with previous 
tuberculosis infection, there were no signs of lymphadenopathy. 
In addition, extensive tests revealed no sign for recurrence of 
breast carcinoma.
Importantly, before the patient developed the clinical 
manifestation of the brainstem symptoms we had demonstrated 
positive NF155- (mean 17.5 IFN-γ spots/106 MNCs) as well as 
NF186-specific T  cell response (28.33 IFN-γ spots/106 MNCs) 
compared to CEF peptide pool specific IFN-γ response (1,062 
IFN-γ spots/106 MNCs) by ELISPOT assay (Figure  1B). In 
comparison, 16 patients with non-immune neuropathy revealed 
no NF155 (mean 0.5 IFN-γ spots/106 MNCs) and NF186 (mean 
0 IFN-γ spots/106 MNCs) with CEF peptide pool specific IFN-γ 
response (519 IFN-γ spots/106 MNCs). Interestingly, NF155 as 
well as NF186 antibodies measured by ELISA according to the 
protocol of Ng et al. (5) were negative.
In the synopsis of all findings, we diagnosed a subacute central 
manifestation of CIDP and escalated the immunomodulatory 
treatment by increasing the dosage of IVIG up to 2 g/kg body 
weight once followed by 1.4  g/kg BW. The patient recovered 
over 6 months reaching complete remission state of vertigo and 
improvement of gait ataxia.
Follow-up MRI scan 18  months later revealed a new, non-
enhancing lesion within the middle cerebellar peduncle and the 
adjacent pons, the previously diagnosed lesion was not did no 
longer show gadolinium enhancement (Figure 1C). A follow-up 
Elispot assay did not show NF-specific T cell response any more 
(0 IFN-γ spots/106 MNCs), while the IFN-γ response against the 
FIgURe 1 | (a) MRI shows pontocerebellar lesion with incomplete peripheral enhancement. (B) Elevated IFNγ response against neurofascin (NF)155 and NF186 
before clinical manifestation in Elispot assay. (C) Follow-up MRI shows new lesion in the middle cerebellar peduncle and adjacent pons without clinical manifestation 
or contrast enhancement. (D) Follow-up Elispot assay shows no IFNγ response against NF.
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CEF control peptide pool was also reduced (mean 169 IFN-γ 
spots/106 MNCs; Figure  1D). NF-specific antibodies remained 
negative. Follow-up CSF remained unchanged with a mild pleo-
cytosis and elevated protein (129 mg/dl) without OCB.
DIsCUssIoN
There is still a controversy whether central manifestation in 
patients suffering from CIDP is a new entity of patients with 
combined central and peripheral demyelination (CCPD) or just 
a coincidence as further “subtype” among the line of atypical 
variants of CIDP. In addition, the underlying pathophysiology 
remains elusive. A recently published retrospective study of five 
patients described a pattern of extensive active demyelination 
of both, central and peripheral nervous system with insufficient 
treatment response with glucocorticosteroids (7). In a Japanese 
case study, patients suffering from CCPD showed a good response 
to IVIG (in 4/4 patients) or PE (in 2/3 patients) (8).
In a recently published retrospective study patients suffering 
from both CNS and PNS involvement (CCPD, n =  31) had a 
more heterogeneous clinical spectrum with frequent post-
infectious onset, primary peripheral nervous system or central 
nervous system involvement, a monophasic or chronic disease 
course, inadequate response to treatments, and a generally poor 
outcome (2). 11 out of 31 CCPD patients had primary PNS 
involvement with GBS-like disease. PNS and CNS involvement 
was simultaneous in 22 patients (71%), CNS preceded PNS 
manifestation in 6 (19%) cases, whereas PNS preceded CNS 
involvement in 3 (10%) (2).
Due to the fact that the majority of the observed patients 
simultaneously or within a short interval affects central and 
peripheral nervous system, an autoimmune response directed 
against common epitopes which are presented in both CNS and 
PNS, is most likely. This autoreactive immune response can be 
mediated by autoreactive T-cells and/or autoantibodies. One 
of these common epitopes may be NF, which is expressed both 
in the CNS and PNS. Interestingly, antibodies directed against 
NF(155) had been described in a small subgroup of CCPD as 
well as in CIDP patients (9, 10). Anti-NF155 IgG4 antibodies 
had been found in patients suffering from CIDP (7%) associated 
with younger age at onset, ataxia, tremor, CNS demyelination 
(8%), and a poor response to IVIG (10). However, in another 
study, none of the patients with primarily PNS involvement had 
antibodies against NF (7) and similarly no anti-NF155 Abs were 
observed in CCPD (2, 11).
Similar to previous reports, our patient demonstrated exten-
sive demyelination and suffered from sensory ataxia and tremor. 
However, in contrast to the majority of previous case reports, our 
patient developed the central manifestation only several years 
after onset of PNS demyelinating disease, which remained stable 
under IVIG-maintenance treatment. Interestingly, escalation of 
IVIG treatment was associated with a remission of clinical symp-
toms due to the central manifestation suggesting an insufficient 
IVIG dosage before. Most interestingly, we found NF155- and 
NF186-specific IFN-γ T cell responses together with an activated 
T  cell reactivity as measured by CEF-specific IFN-γ response 
before clinical onset of brainstem manifestation. Interestingly, in 
a cohort study of typical and atypical CIDP patients, we found 
NF155- and NF186-specific T cell response in some patients but 
no specific antibody response (in submission). At the time of clini-
cal remission and after high-dosage IVIG treatment, NF-specific 
T cell responses turned negative in the peripheral blood, which 
may support the role of NF as a pathogenically relevant epitope 
in CCPD. As we have demonstrated previously efficient IVIG 
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treatment leads to reduction of CD8+ effector memory T cells 
(3), which may have led to reduced NF and thus clinical remission 
in the presented case.
In summary, the clinical presentation of CIDP with a central 
manifestation upon immunomodulatory treatment a decade after 
disease onset differs from so-far described CCPD cases and may 
present a novel subtype of CIDP. For the first time, we found a 
NF155- and NF186-specific T cell response before clinical onset 
of a central manifestation in CIDP patients. NF may therefore 
function as a specific antigen capable to elicit T and/or B cell auto-
reactive response in peripheral and central demyelinating disease.
etHICs stateMeNt
The patient here gave her written consent as part of a cohort 
study before the study. The cohort study was approved by ethical 
committee of Charité University Medicine Berlin. This study was 
carried out in accordance with the recommendations of ethical 
committee Charité University Medicine Berlin with written 
informed consent from all subjects. All subjects gave written 
informed consent in accordance with the Declaration of Helsinki. 
The protocol was approved by the by ethical committee of 
Charité University Medicine Berlin. All patients were recruited 
in the outpatient clinic of Charité Department of Neurology. For 
Elispot assay control, we included 16 age-matched patients suf-
fering from non-immune neuropathies.
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